Alfuzosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Alfuzosin
- Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Alfuzosin is an alpha-1 adrenergic blocker originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but no clinical trials and no publications currently support this direction. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign prostatic hyperplasia (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Alfuzosin is known as an alpha-1A-selective adrenergic antagonist, and its efficacy in BPH is established. This relaxes smooth muscle in the prostate and bladder neck and eases urinary symptoms.
The predicted indication is a different kind of disease. Ambras syndrome is a rare congenital hypertrichosis linked to chromosome 8q22 rearrangements that affect TRPS1 regulation. No plausible pathway connects alpha-1 blockade to this genetic hair-growth disorder. The very high score (99.99%) reflects knowledge-graph inference only, and it is probably driven by shared neighbours among hair-related nodes.
The other top predictions show the same pattern. Most are rare hair disorders or congenital malformation syndromes (hypertrichosis, trichomegaly, hypotrichosis, hair shaft abnormalities, Dandy-Walker and dental/periodontal malformation syndromes). Allergic urticaria and persistent fetal circulation syndrome are also predicted. None has trial or literature support, and none has a credible mechanistic link. Persistent fetal circulation syndrome is conceptually related to vasodilation, but alfuzosin has no neonatal safety data and carries a risk of hypotension.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09546P | XATRAL SR TABLET 5 mg | Extended-release tablet | Not stated in the licence record |
| SIN13984P | RANFUZOSIN MODIFIED RELEASE TABLETS 10MG | Extended-release tablet | Not stated in the licence record |
| SIN15512P | APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg | Extended-release tablet | Not stated in the licence record |
| SIN11579P | XATRAL XL TABLET 10 mg | Tablet | Not stated in the licence record |
All four registrations are valid single-ingredient oral products.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, hypotensive disorder, long QT syndrome (including familial), torsades de pointes, liver failure, liver disease, gallbladder disease, and intraoperative floppy iris syndrome.
- Drug Interactions: 100 interactions were identified. Of those reviewed, the Major ones are:
- Cisapride
- Clarithromycin
- Dolasetron
Most other reviewed interactions are Moderate, including famotidine, aprepitant, bupropion, levofloxacin, granisetron, several SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) and several laxatives. Cimetidine is Minor. The QT-related and CYP3A4-related interactions need particular attention.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score. There are no clinical trials or publications, and no plausible mechanism links alpha-1A blockade to Ambras syndrome or to the other predicted conditions. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data (MOA) for alfuzosin
- Package insert warnings and contraindications from HSA, which are needed for safety screening
- Preclinical or mechanistic evidence linking alpha-1 blockade to hair-follicle biology or TRPS1-related pathways
- Evidence on whether any of the lower-ranked predictions (for example allergic urticaria) have better scientific support
- A route-of-administration and formulation compatibility assessment. Current products are oral only.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.